Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Osiris Therapeutics (OSIR) to be Acquired by Smith & Nephew (SNN) for $19/Share
-
Former SEC Commissioner Michael Piwowar to Serve as a Senior Advisor to GTS, the Largest Market Maker at the NYSE
-
Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
-
Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
-
UnitedHealth Group (UNH) POS Rebate Requirement Shows Its Dominance - Cantor
-
Cantor Fitzgerald Reiterates Overweight Rating on Health Insurance Innovations (HIIQ)
-
Cantor Fitzgerald Reiterates Overweight Rating on Array BioPharma (ARRY)
-
Cantor Fitzgerald Reiterates Overweight Rating on eHealth (EHTH)
-
Cantor Fitzgerald Reiterates Overweight Rating on Ovid Therapeutics Inc (OVID)
-
Cantor Fitzgerald Reiterates Overweight Rating on Tivity Health (TVTY)
-
UPDATE: Cantor Fitzgerald Starts Crinetics (CRNX) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Seres Therapeutics (MCRB)
-
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
-
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
-
Spring Bank Pharmaceuticals (SBPH) PT Cut At Cantor After Inarigivir Lauch Delay
-
PolarityTS (PTE) Reiterated Overweight At Cantor After FDA Update
-
Omnicell (OMCL) PT Raised to $91 at Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades McEwen Mining Inc. (MUX:CN) (MUX) to Hold
-
Cantor Likes uniQure BV (QURE) as Spark (ONCE) Proxy Shows Significant Interest in the Sector
-
Cantor Fitzgerald and Silverstein Properties Announce Joint Venture Focused on Opportunity Zone Investments
-
Pre-Open Stock Movers 03/07: (ARQL) (ALSK) (GWRE) Higher; (APVO) (BPI) (KR) Lower (more...)
-
Apellis Pharmaceuticals (APLS) Prices 6M Share Common Offering at $17/Sh
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Cantor Fitzgerald Starts Chiasma (CHMA) at Overweight
-
ProPhotonix Awarded Two US Patents UV LED Curing - 07/03/2019
-
Cantor Fitzgerald Starts Unity Biotechnology Inc (UBX) at Overweight
-
Apellis Pharmaceuticals (APLS) to Offer $75M in Common Stock
-
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Sarepta Therapeutics (SRPT) Defended at Cantor Fitzgerald
-
Pre-Open Stock Movers 03/06: (ANF) (ZAYO) (AMBA) Higher; (VLRX) (CLDX) (PRMW) Lower (more...)
-
Marinus Pharma (MRNS) Second Phase 3 Is An Incremental Positive - Cantor
-
CymaBay Therapeutics (CBAY) Prices 8M Common Stock Offering at $12.50/Share
-
CymaBay Announces Pricing of Public Offering of Common Stock
-
UPDATE: Cantor Fitzgerald Starts Voyager Therapeutics (VYGR) at Overweight
-
Ascendis Pharma (ASND) Prices 4.166M ADS Offering at $120/ADS
-
Rambler Metals & Mining PLC announces Appointment of New CFO
-
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
-
CymaBay Therapeutics (CBAY) to Offer Common Stock
-
CymaBay Announces Proposed Public Offering of Common Stock
-
Freddie Mac Prices $1.2 Billion Multifamily K-Deal, K-088
-
AIMCo Completes Acquisition of Majority Stake in Eolia
-
Mereo BioPharma to Present at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019
-
Mereo BioPharma to Present at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019
-
UPDATE: Cantor Fitzgerald Starts Mirati Therapeutics (MRTX) at Neutral
-
Ascendis Pharma (ASND) PT Raised to $185 at Cantor Fitzgerald
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $131 at Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades Nightstar Therapeutics (NITE) to Neutral

